1-(2,3-二氢-1,4-苯并二噁英-6-基)-n-甲基甲胺 | 613656-45-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 1-(2,3-二氢-1,4-苯并二噁英-6-基)-n-甲基甲胺
• 中文别名: 1-(2,3-二氢-1,4-苯并二噁英-6-基)-N-甲基甲胺
• 英文名称: N-methyl-1,4-benzodioxan-7-ylmethylamine
• 英文别名: (2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)methylamine；N-methyl-3,4-ethylenedioxy-benzylamine；N-methyl-3,4-ethylenedioxybenzylamine；1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-methylmethanamine
• CAS: 613656-45-4
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD06260669
• 分子量: 179.219
• InChiKey: SAGRVQMJUPNRRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-(2,3-二氢-1,4-苯并二噁英-6-基)-n-甲基甲胺 在 盐酸 、 potassium carbonate 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 (2E,4E)-N-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-N-methyl-5-[4-(trifluoromethyl)phenyl]penta-2,4-dien-1-amine;hydrochloride
  参考文献：
  名称：

  Novel Staphyloxanthin Inhibitors with Improved Potency against Multidrug Resistant Staphylococcus aureus

  摘要：

  Diapophytoene desaturase (CrtN) is a potential novel target for intervening in the biosynthesis of the virulence factor staphyloxanthin. In this study, 38 1,4-benzodioxan-derived CrtN inhibitors were designed and synthesized to overwhelm the defects of leading compound 4a. Derivative 47 displayed superior pigment inhibitory activity, better hERG inhibitory properties and water solubility, and significantly sensitized MRSA strains to immune clearance in vitro. Notably, 47 displayed excellent efficacy against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate MRSA, VISA), and NRS271 (linezolid-resistant MRSA, LRSA) comparable to that of linezolid and vancomycin in vivo.

  DOI：

  10.1021/acsmedchemlett.7b00501
• 作为产物：
  描述：

  1,4-苯并二恶烷-6-甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 1-(2,3-二氢-1,4-苯并二噁英-6-基)-n-甲基甲胺
  参考文献：
  名称：

  Novel Staphyloxanthin Inhibitors with Improved Potency against Multidrug Resistant Staphylococcus aureus

  摘要：

  Diapophytoene desaturase (CrtN) is a potential novel target for intervening in the biosynthesis of the virulence factor staphyloxanthin. In this study, 38 1,4-benzodioxan-derived CrtN inhibitors were designed and synthesized to overwhelm the defects of leading compound 4a. Derivative 47 displayed superior pigment inhibitory activity, better hERG inhibitory properties and water solubility, and significantly sensitized MRSA strains to immune clearance in vitro. Notably, 47 displayed excellent efficacy against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate MRSA, VISA), and NRS271 (linezolid-resistant MRSA, LRSA) comparable to that of linezolid and vancomycin in vivo.

  DOI：

  10.1021/acsmedchemlett.7b00501

文献信息

• 苯并含氧脂肪环甲胺类化合物
  申请人：华东理工大学

  公开号：CN108117534B

  公开（公告）日：2021-02-05

  本发明提供了一种苯并含氧脂肪环取代甲胺类化合物及其用途，涉及所述苯并含氧脂肪环取代甲胺类化合物即式I所示化合物或其药学上可接受的盐，以及其在制备金黄色葡萄球菌金黄色色素合成抑制剂类抗菌药物中的运用。
• [EN] DPP-IV INHIBITORS<br/>[FR] INHIBITEURS DE LA DPP-IV
  申请人：GRAFFINITY PHARMACEUTICALS AG

  公开号：WO2005095343A1

  公开（公告）日：2005-10-13

  The invention relates to compounds of formula (I), Z-C(R<1>R<2>)-C(R<3>NH2)-C(R<4>R<5>)-X-N(R<6>R<7>), wherein Z, R<1-7> and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-lV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式(I)的化合物，其中Z-C(R1R2)-C(R3NH2)-C(R4R5)-X-N(R6R7)，其中Z，R1-7和X的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备此类化合物以及其作为药物的生产和使用。
• [EN] HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY<br/>[FR] COMPOSES HETEROCYCLIQUES, PROCEDES DE PRODUCTION DE CEUX-CI ET UTILISATION DE CEUX-CI DANS UN TRAITEMENT
  申请人：AFFINIUM PHARM INC

  公开号：WO2004052890A1

  公开（公告）日：2004-06-24

  In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.

  在某种程度上，本发明涉及公式（I）的抗菌化合物，其中A是一个双环杂芳基环或三环环，R2是一个杂环残基；L是一个键，或者L是烷基，烯基或环烷基。
• Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents
  作者：Dongguang Fan、Bin Wang、Giovanni Stelitano、Karin Savková、Rui Shi、Stanislav Huszár、Quanquan Han、Katarína Mikušová、Laurent R. Chiarelli、Yu Lu、Chunhua Qiao

  DOI：10.1021/acs.jmedchem.1c01049

  日期：2021.10.14

  exploration introduced five-member aromatic heterocycles as linkers to attach an aryl group as the side chain. Our work led to the discovery of a number of BTZ derived compounds with potent antitubercular activity. The optimized compounds 6 and 38 exhibited MIC 47 and 30 nM, respectively. Compared to PBTZ169, both compounds displayed increased aqueous solubility and higher stability in human liver microsomes

  苯并噻嗪酮 (BTZ) 支架化合物 PBTZ169 通过抑制必需的黄素酶 DprE1 杀死结核分枝杆菌，从而阻断细胞壁成分阿拉伯聚糖的合成。虽然最小抑制浓度 (MIC) 低于 0.2 ng/mL，对结核分枝杆菌非常有效，但其低水溶性和生物利用度问题仍需解决。在这里，我们设计并合成了一系列6-甲磺酰基取代的BTZ类似物；进一步的探索引入了五元芳族杂环作为连接体以连接芳基作为侧链。我们的工作导致发现了许多具有强效抗结核活性的 BTZ 衍生化合物。优化的化合物6和38分别表现出 MIC 47 和 30 nM。与 PBTZ169 相比，这两种化合物在人肝微粒体中均表现出更高的水溶性和更高的稳定性。该研究表明，可以实施替代侧链修饰策略来改善基于 BTZ 的化合物的药物性质。
• Isoquinolines as IGF-1R Inhibitors
  申请人：Gunzinger Jan

  公开号：US20090099229A1

  公开（公告）日：2009-04-16

  Compounds of the formula (I): were synthesized. In at least one embodiment, they were found to down-regulate or inhibit the expression or function of the IGF-1 receptor.

  公式（I）的化合物被合成。在至少一个实施例中，发现它们能够下调或抑制IGF-1受体的表达或功能。